THERAPY DOSSIER · th-81c6a2c8fc5e

Methacrylate hydrogel scaffolds: hydroxypropylmethacrylamide (HPMA), 2-hydroxyethylmethacrylate (HEMA), and HEMA with attached fibronectin (HEMA-Fn)

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30131482 ↗2018Mixed findings

Modified Methacrylate Hydrogels Improve Tissue Repair after Spinal Cord Injury.

RatSpinal cord injuryHemisection / partialWistarMalen = 34 male Wistar rats in total across groupsIntraspinal implantation into the lesion cavityAcute, at the time of spinal cord injury

Model: Spinal cord hemisection at the T8 level with acute hydrogel implantation

HPMA and HEMA-Fn scaffolds produced partial sensory improvement compared with control and plain HEMA animals. HPMA showed increased connective tissue infiltration and significantly greater axonal ingrowth than HEMA-Fn and plain HEMA. HEMA-Fn showed a non-significant tendency towards greater connect…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…